Artificial Intelligence in Drug Development

Artificial Intelligence(AI) has emerged as a revolutionary in drug development, significantly transforming traditional pharmaceutical research processes. Conventional drug discovery is time consuming, costly and associated with high failure rates, often requiring more than a decade for successful drug approval. AI technologies such as Machine Learning(ML), Deep Learning(DL) and Natural Language Processing(NLP) provide advanced computational tools that accelerates drug discovery, improve prediction accuracy and enhance decision making throughout the development pipeline. AI application include target identification, biomarker discovery, drug design, toxicity prediction, drug purposing and optimization of clinical trials. In preclinical studies, AI assists in predicting toxicity, analyzing biomedical data and improving pharmacokinetic and pharmacodynamic modeling. During clinical trials, AI supports patient selection, adherence monitoring, endpoint detection and trial optimization, thereby reducing time and cost.AI also enables personalized medicine through the analysis of genomics, proteomics and clinical data. Despite its numerous advantages, challenges such as data privacy, lack of standardized regulations, interpretability of AI models and shortage of skilled professionals remain significant barrier to implementation. Neverthless, ongoing advancements in AI and increasing integration of healthcare data are expected to further enhance pharmaceutical research and healthcare outcomes. Overall, AI has the potential to revolutionize drug development by improving efficiency, reducing costs and increasing the success rate of discovering safe and effective medicines.